Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Patent
1992-06-12
1995-08-01
Rollins, John W.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
800DIG23, Plt100, A61K 3578
Patent
active
054378664
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The invention is related to treatments effective in treating malignancies. In particular, it concerns extracts of plants which, when used in a specified protocol, are effective against these conditions.
BACKGROUND ART
It is understood that malignancy is a highly refractory disease against which a number of treatments have been recognized in Western societies as at least palliative--including surgery, chemotherapy, radiation therapy and photodynamic therapy. However, although the mechanisms and etiology of the disease are incompletely understood, it is recognized that the victim of the disease is capable in many cases of marshalling indigenous defenses. Indeed, it is believed that the condition occurs because of the breakdown of these natural defenses.
Accordingly, materials which enhance the capability of the subject to mount its own defense are useful in treatment. The present invention describes such compositions and protocols.
DISCLOSURE OF THE INVENTION
The invention is directed to a protocol of administration of the combination of extracts of Letinus edodes plants, mung bean, Hedyotis diffusa (wild) and the herb Scutellaria barbata.
Thus, in one aspect, the invention is directed to a method of treating a subject afflicted with a malignant condition which method comprises daily administration of the combination of: Hedyotis diffusa and 50 g of Scutellaria barbata, extracted together.
In preferred embodiments, all four extracts are administered daily.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGS. 1A and 1B show the effect of the diet of the invention on tumor growth in murine model 1.
FIGS. 2A and 2B show the results, in an additional experiment, of the effect of the invention diet on tumor growth in murine model 1.
FIGS. 3A and 3B show the effect of the invention diet on tumor growth in murine model 2.
FIG. 4 shows a comparison of the tumor size in treated and untreated mice.
MODES OF CARRYING OUT THE INVENTION
As used herein, "cooked aqueous extract" refers to an extract prepared by boiling the relevant plant or portion thereof in water, optionally containing additional materials for flavoring. The extract may be decreased in volume if desired.
Preferred methods for preparing the required: extracts are as follows: macerated in a food processor and is cooked with meat or chicken as soup for at least 5 minutes at 100.degree. C. The plant is known to contain several polysaccharides, which are known to stimulate natural killer cell activity. soften the bean, and the whole bean is eaten. A boiled extract is, however, preferred. This is prepared by grinding the beans, e.g., in a coffee grinder and boiling at 100.degree. C. for 5 minutes. Preferably, however, the cooked extract is used.
Mung bean is known to contain nucleases as well as protease inhibitors. Nucleases hydrolyze single-stranded DNA; when cancer cells proliferate, their DNAs change to single-stranded DNA first, which could be digested by mung bean nucleases. Proteases could facilitate metastasis of cancer cells. Mung bean protease inhibitors may have the effect of preventing cancer metastasis. daily amount. The herb should be washed with water, covered with water, and cooked together with 50 g of Scutellaria barbata (see paragraph 4), and 10 of the root of Glycyrrhiazuralensis fisch as a sweetener. This herb is known to inhibit the growth of tumor S-180, U.sub.14 and L1 ascites. The herbs should not be eaten; only the soup should be drunk once or twice a day. The soup should be cooked down to the volume of a coffee cup. (wild). This herb is known to inhibit the growth of tumor S-180, ascites and T22.
The protocol can be administered orally as set forth above, and it should be noted that extracts 3 and 4 may be supplied on less than a daily basis. However, at least one administration of these extracts should be included in the protocol.
The continuance of the regimen of the invention, along with a proper balanced diet results in continued amelioration of malignancy. Further, the regimen is a suitable preparation for surgic
REFERENCES:
patent: 4461760 (1984-07-01), Sugano et al.
patent: 4760053 (1988-07-01), Labrie
Sasaki S., "Antitumor Agents From Medicinal Plant," Chemical Abstracts (23 Jan. 1984) vol. 100, No. 4, abstract No. 26026w.
Bhakuni D. et al., "Medicinal Plants. III. Ericaceae and Other Families. Chemical Constituents of Actinodaphne augustifolia, Croton sparsiflorus, Duabanga sonneratiodes, glycosmis mauritiana, Hedyotis auricularia, Lyonia ovalifolia, Micromelum pubescens, pyrus pashia and Rhodendron niveum," Chemical Abstracts (6 Dec. 1971) vol. 75, No. 23, abstract No. 137510j.
Chem. Abst. 100(U):26026w, 1984.
Chem. Abst. 75(23):137510; 1971.
Lee Howard C.
Rollins John W.
LandOfFree
Herbal treatment of malignancy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Herbal treatment of malignancy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Herbal treatment of malignancy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-732761